References
- Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12
- Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011;11:1226-35
- Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83
- Lamb KEL, Sundus A, Meier-Kriesche, et al. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62
- Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95
- Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014;14:255-71
- Mengel M, Sis B, Haas M, et al; Banff meeting report writing committee. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12:563-70
- Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010;10:2223-30
- Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99
- Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation 2007;83:858-73
- Dharancy S, Giral M, Tetaz R, et al. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin Transplant 2012;26:E293-9
- Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005;16:1839-48
- National Health Service Business Services Authority. Prescription Cost Analysis (PCA) Data. Newcastle upon Tyne: National Health Service Business Services Authority, 2013. http://www.nhsbsa.nhs.uk/PrescriptionServices/3494.aspx. Accessed March 19, 2015
- Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009;9:1063-71
- Kim M, Martin ST, Townsend KR, et al Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy 2014;34:733-44
- European Medicines Agency Committee for Orphan Medicinal Products. Minutes of the 4 – 6 February 2014 meeting. London: European Medicines Agency, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2014/04/WC500165700.pdf. Accessed March 19, 2015
- Kuypers DR, Peeters PC, Sennesael JJ, et al; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013;95:333-40
- R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2012. ISBN 3-900051-07-0. http://www.R-project.org/. Accessed June 19, 2015
- Goulet V, Dutang C, Maechler M, et al. [email protected]. expm: Matrix exponential. R package version 0.99-1.1. Zürich: expm Developers, 2014. http://CRAN.R-project.org/package=expm. Accessed June 19, 2015
- Edinburgh Renal Unit. Transplant Handbook. Treatment of Acute antibody mediated rejection. Edinburgh: Edinburgh Renal Unit, 2013. http://www.edren.org/pages/handbooks/transplant-handbook/immunosuppression-protocol/treatment-of-acute-antibody-mediated-rejection.php. Accessed March 19, 2015
- Joint Formulary Committee. British National Formulary. 68th ed. London: BMJ Group and Pharmaceutical Press, 2014
- National Health Service. NHS reference costs 2013 to 2014. London: National Health Service, 2014. https://www.gov.uk/government/publications/nhsreference-costs-2013-to-2014. Accessed July 28, 2015
- NHS Blood and Transplant. Cost-effectiveness of transplantation. Watford: National Health Service Blood Transplant, 2009. http://www.organdonation.nhs.uk/newsroom/fact_sheets/cost_effectiveness_of_transplantation.asp. Accessed May 12, 2015
- The Renal Association. Clinical Practice Guidelines Module 2: Haemodialysis. Petersfield: The Renal Association, 2007. http://www.renal.org/docs/default-source/guidelines-resources/Module_3a_-_Haemodialysis_-_4th_Edition.pdf. Accessed May 12, 2015
- Krämer BK, Charpentier B, Bäckman L, et al; Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once daily (Advagraf) versus twice daily (Prograf) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010;10:2632-43
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5-14
- The National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: The National Institute for Health and Care Excellence, 2013. http://www.nice.org.uk/article/PMG9/chapter/Foreword. Accessed March 19, 2015
- Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009;9:2597-606
- Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004;77:769-76
- Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1
- Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009;23:63-73
- Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008;12:1754-61
- Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011;8:e61-6
- Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30
- Sabbatini M, Garofalo G, Borrelli S, et al. Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence 2014;8:73-81
- Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc 2013;45:2314-20
- Beckebaum S, Iacob S, Sweid D, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int 2011;24:666-75
- Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transplant 2012;12:193724
- Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(3 Suppl):S1-155
- Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011;11:56-65
- Guirado L, Cantarell C, Franco A, et al; GREAT Study Group. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011;11:1965-71